Trial reportEuropean journal of nuclear medicine and molecular imaging2019
Influence of lanreotide on uptake of
Trial report in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 56 citations in OpenAlex.
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Gallium-Containing Agents for Tumor Diagnosis and Therapy: Current Status and Future Prospects.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Drug interactions involving therapeutic radiopharmaceuticals: a systematic review.EJNMMI radiopharmacy and chemistry · 2026Review
- Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.Experimental hematology & oncology · 2024Review
- Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.Theranostics · 2024Review
- Letter to the editor regarding "The effect of long-acting somatostatin analogs on the uptake of [European journal of nuclear medicine and molecular imaging · 2023Article
- Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- The effect of long-acting somatostatin analogues on the uptake of [European journal of nuclear medicine and molecular imaging · 2023Article
- A physiologically based pharmacokinetic model for [EJNMMI research · 2023Article
- Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [Frontiers in oncology · 2023Article
- A personal acquisition time regimen ofCancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Somatostatin receptor saturation after administration of high peptide amounts of [EJNMMI research · 2022Article
- Review
- Influences on PET Quantification and Interpretation.Diagnostics (Basel, Switzerland) · 2022Review
- The Diagnostic and Grading Accuracy ofFrontiers in oncology · 2022Article
- Review
- Receptor depletion and recovery in small-intestinal neuroendocrine tumors and normal tissues after administration of a single intravenous dose of octreotide measured byEJNMMI research · 2021Article
- Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake ofMolecular imaging and biology · 2021Article
- Combination Therapies with PRRT.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSomatostatin receptor imaging with PET is the standard of care for patients with a neuroendocrine tumour (NET). Since therapy and imaging with somatostatin analogues utilize the same receptor, current guidelines recommend withdrawing long-acting somatostatin analogues for 3-4 weeks prior to somatostatin receptor PET imaging. The aim of this study is to prospectively assess the effect of lanreotide use on the uptake of
methodsThirty-four patients with metastatic and/or unresectable NET and currently on lanreotide therapy for at least 4 months were included in the study. A
resultsOf the 34 patients included, 31 were available for analyses in which 190 tumour lesions were measured. Uptake of
conclusionLanreotide injection prior to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.